Impact Factor
4.61
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
13.80
3,007 total citations
h5-index
79
h5 depth signal
Cited share
75.7%
178 of 235
Total citations
3,007
Citation footprint
Metric signal
16.36
External metric anchor
Self-citation
0.6%
17 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
China
527
United States
135
South Korea
48
Germany
45
France
25
Citing Fields of Research
Oncology
300
Immunology
206
Cancer & Development
196
Cancer, Autophagy & Apoptosis
106
Liver & Colon Cancer
101
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
948
Articles tracked across the journal lifetime
Indexed publication set
235
178 cited publications
Last 12 months
82
13.7 publications/month
Open access share
72.0%
59 OA publications in the last year
Leading citing country
China
527 citing publications
Leading citing field
Oncology
300 citing publications
Latest tracked publication
20 October 2026
10 recent records available
Coverage & Indexing History
v38, Mar. 2018-
v38, Mar. 2018-
Active Coverage
Research Focus & Classification
Indexed Subjects
Immunology
Oncology
Cancer & Development
Lung Cancer
Cancer, Autophagy & Apoptosis
Issuing & Sponsoring Bodies
Contributor
Zhongshan da xue (Guangzhou, China). Zhong liu fang zhi zhong xin
Contributor
Zhongguo kang ai xie hui
Contributor
US Chinese Anti-Cancer Association
Broad Categories
Neoplasms
Immunology
Cancer, Autophagy & Apoptosis
Lung Cancer
Breast Cancer
Liver & Colon Cancer
Digestive Disorders
MeSH Descriptors
Neoplasms
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
02
03
DOI 10.34133/cancomm.0066
Open DOI
SLC38A2-Driven Glutamine Metabolic Reprogramming Promotes Hypoxic Survival in Glioblastoma
04
05
06
DOI 10.34133/cancomm.0063
Open DOI
SHMT2 K280 Succinylation Drives ICC Progression via S100A8+ Neutrophil-mediated Immunosuppression
07
DOI 10.34133/cancomm.0062
Open DOI
Leveraging innate immune and metabolic cell death pathways in cancer therapies
08
DOI 10.34133/cancomm.0042
Open DOI
NSUN2 Promotes Cancer Immune Evasion via its Moonlighting Function Acting on Metabolic Reprogramming
Background: Although cancer immunotherapies have revolutionized cancer treatment, a substantial proportion of patients remain unresponsive. Elucidating the molecular mechanisms underlying tumor imm...
09
DOI 10.34133/cancomm.0041
Open DOI
Short-course Radiotherapy-based Total Neoadjuvant Therapy plus Tislelizumab for Locally Advanced Rectal Cancer (Neo-STAR): Early Outcomes of a Randomized Phase II Trial
Background: Short-course radiotherapy (SCRT)-based total neoadjuvant therapy (TNT) is used for locally advanced rectal cancer (LARC). However, the pathological complete response (pCR) rate still hovers around 30%. Radiotherapy and immune...
10
DOI 10.34133/cancomm.0039
Open DOI
Macrophages drive ferroptosis resistance after radiotherapy
Background: Radiotherapy eliminates most tumor cells but spares persister tumor cells that evade cell death and drive relapse. Increasing evidence suggests that stromal components of the tumor microenvironment influence treatment respons...
Bibliographical & Catalog Notes
Affiliated with Chinese Anti-Cancer Association and US Chinese Anti-Cancer Association.